HER2-positive Breast Cancer Registry
ConditionHER2 + Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPriyanka Sharma
About this trial
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Stage I-IV HER2-positive breast cancer
Disqualifiers
None
Trial population
Patients with stage I-IV HER2-positive breast cancer.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
1,000 Participants
are grouped into 1 trial groupGroup A: HER2-positive breast cancer
Trial outcomes
Primary outcomes
1
Overall survival rate
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
Time frame
From diagnosis to 5 years after diagnosisSecondary outcomes
1
Pathologic complete response rate
Percentage of patients with stage I-III HER2-positive breast cancer who received neoadjuvant systemic therapy and experienced pathologic complete response.
Time frame
From start of neoadjuvant systemic treatment until approximately 8 months after start of neoadjuvant systemic treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Priyanka Sharma
Lead sponsor
University of Kansas Medical Center
Sponsor institution
Source ClinicalTrials.gov